Chemotherapy for Brain Metastases in Small-Cell Lung Cancer

Chen, Gigi; Huynh, Minh; Chen, Allan; Fehrenbacher, L.; Gandara, David R.; Lau, Derick H

doi:10.3816/clc.2008.n.006

Cited by 37 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment regimens, which lead to measurable survival benefit include complete surgical excision, chemotherapy (in testicular cancer, lymphomas, and small cell lung cancer; ref. 16), or stereotactic irradiation. However, surgical excision can only be carried out in patients with one or a few brain metastases.…”

Section: Introductionmentioning

confidence: 99%

Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

Poli

Bianchi

Virotta

et al. 2013

Cancer Immunology Research

View full text Add to dashboard Cite

Radioimmunotherapy (RIT) with 131 I-labeled L19SIP (radretumab; a small immunoprotein format antibody directed against the ED-B domain of fibronectin; $80 kDa molecular weight) has been investigated in several clinical trials. Here, we describe the use of immuno-PET imaging with iodine-124 ( 124 I)-labeled L19SIP to predict doses delivered to tumor lesions and healthy organs by a subsequent radretumab RIT in patients with brain metastases from solid cancer. Bone marrow doses were evaluated both during the diagnostic phase and posttherapy, measuring activities in blood (germanium detector) and whole body (lanthanum bromide detector). Expected doses for radretumab administration (4,107 MBq/m 2 ) were calculated from data obtained after administration of an average of 167 MBq 124 I-L19SIP to 6 patients. To assess lesion average doses, the positron emission tomography (PET) scanner was calibrated for the use of 124 I with an International Electrotechnical Commission (IEC) Body Phantom and recovery coefficients were calculated. The average dose to bone red marrow was 0.21 Gy/GBq, with high correlation between provisional and actual posttherapy doses. Although the fraction of injected activity in normal organs was similar in different patients, the antibody uptake in the neoplastic lesions varied by as much as a factor of 60. Immuno-PET with 124 I-labeled L19SIP offers significant advantages over conventional 131 I imaging, in particular accuracy of dosimetric results. Furthermore, the study indicates that antibody uptake can be highly variable even in different lesions of the same patient and that immuno-PET procedures may guide product development with armed antibodies. Cancer Immunol Res; 1(2); 134-43. Ó2013 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

Poli

Bianchi

Virotta

et al. 2013

Cancer Immunology Research

View full text Add to dashboard Cite

show abstract

“…Some patients with SCLC respond to systemic chemotherapy, either as initial therapy for previously untreated brain metastases or for recurrence of brain metastases after prior whole brain RT (Franciosi et al, 1999;Chen et al, 2008). Some patients with SCLC respond to systemic chemotherapy, either as initial therapy for previously untreated brain metastases or for recurrence of brain metastases after prior whole brain RT (Franciosi et al, 1999;Chen et al, 2008).…”

Section: Treatmentmentioning

confidence: 99%

Neurologic complications of lung cancer

Dropcho

2014

Handbook of Clinical Neurology

View full text Add to dashboard Cite

“…The response rates of the primary tumor are not given in these reports. Chen et al (80) reported a high response rate of 65% with a combination of carboplatin and irinotecan. In an analysis by Schuette et al (77) and Korfel et al (79), response rates for brain metastases of 50 and 33%, respectively, were achieved with topotecan.…”

Section: Front-line Chemotherapymentioning

confidence: 99%

“…Second-line chemotherapy SCLC relapse may also require systemic chemotherapy, which showed efficacy in 7 small phase II studies (74)(75)(76)(77)(78)(79)(80) with chemotherapy as salvage treatment after failing systemic chemotherapy and WBRT (Table VII). Response rates are generally lower and survival is decreased in patients who receive chemotherapy for brain metastases after failure following radiotherapy.…”

Section: Front-line Chemotherapymentioning

confidence: 99%

Medical management of brain metastases from lung cancer (Review)

Yamanaka¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Brain metastases are a frequent complication in patients with lung cancer and a significant cause of morbidity and mortality. The prognosis of these patients is poor. Medical therapies for brain metastases are neither wellstudied nor established. This review analyzes the impact of medical treatment on survival by reviewing recent articles of the management of brain metastases from lung cancer patients. Chemotherapy for brain metastases from lung cancer is effective for both small cell and non-small cell lung cancer. Since brain metastases are part of systemic progression, chemotherapy should always be considered for the therapeutic management of brain metastases. Available data and response rates in lung cancer patients indicated that medical treatment for the management of brain metastases should be part of a multimodality treatment.

show abstract

Chemotherapy for Brain Metastases in Small-Cell Lung Cancer

Cited by 37 publications

References 18 publications

Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

Neurologic complications of lung cancer

Medical management of brain metastases from lung cancer (Review)

Contact Info

Product

Resources

About